Episealer® Patellofemoral System available in United Arab Emirates

Episurf Medical (NASDAQ: EPIS B) today announces that the Ministry of Health & Prevention in the United Arab Emirates has issued a classification letter for the company’s implant technology Episealer® Patellofemoral System, allowing sales in the United Arab Emirates market. The classification follows after a review process.

“As soon as we got the Episealer® Patellofemoral System clearance in the United States, we started the regulatory work of bringing the technology to other markets. The United Arab Emirates is now the second country that cleared the product for sale, and we are continuing to make progress in the regulatory work in other countries too. It’s exciting to be able to help even more people by bringing this product to new markets “, says Pål Ryfors, CEO, Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:00 CEST on 20 June, 2023.

Tags: